Effectiveness, treatment durability, and treatment costs of canagliflozin and glucagon-like peptide-1 receptor agonists in patients with type 2 diabetes in the USA

Effectiveness, treatment durability, and treatment costs of canagliflozin and glucagon-like peptide-1 receptor agonists in patients with type 2 diabetes in the USA

Introduction This real-world study compared glycemic effectiveness, treatment durability, and treatment costs with canagliflozin 300 mg versus any dose of glucagon-like peptide-1 (GLP-1) receptor agonists in patients with type 2 diabetes mellitus (T2DM) in the USA.Research design and methods A retro...

Full description

Saved in:
Bibliographic Details
Main Authors: Mukul Singhal, Hiangkiat Tan, Craig I Coleman, Michelle Han, Chi Nguyen, Michael Ingham
Format: Article
Language:English
Published: BMJ Publishing Group 2019-05-01
Series:BMJ Open Diabetes Research & Care
Online Access:https://drc.bmj.com/content/7/1/e000704.full
Tags: Add Tag
No Tags, Be the first to tag this record!

Similar Items

Similar Items